Showing 35,310 articles by Roger Pebody

Filters Author: Roger Pebody

Roger joined aidsmap in 2008 and was Managing Editor from 2018 to 2024. As a freelancer, he now edits aidsmap’s news and conference coverage, as well as working on updates to About HIV pages. He is also a contributing science editor for TheBodyPro, a freelance journalist for The Lancet HIV, and a medical writer helping researchers prepare articles for peer-reviewed journals. He began working on HIV at Gay Men Fighting AIDS in the mid-1990s.

Testing & health monitoring

Study: Delay lab tests in low-risk HIV patients to minimize COVID-19 exposure

Editor's pick
Healio
24 November 2020
Drug policy & policing

Policy Insight: UK government drugs experts recommend reclassifying GHB to a Class B drug

Editor's pick
Volteface
24 November 2020
How HIV works

Viral Reservoir’s Production of HIV RNA Tied to Harmful Inflammation

Editor's pick
POZ
23 November 2020
Coronavirus

Switzerland: HIV infections drop by a third

Editor's pick
Swiss Info
23 November 2020
Ethnic & cultural minorities

UK: Black people less likely to be engaged in HIV care, with more cases of viral rebound

News
23 November 2020
People & personal stories

'We need to be honest': the PHE expert shining light on Covid and inequality

Editor's pick
The Guardian
23 November 2020
Experiences of stigma

Very poor knowledge of HIV among staff at major London hospitals

News
23 November 2020
Mental & emotional health & wellbeing

How middle-aged queer men have prevailed over four decades of HIV/AIDS

Editor's pick
CTV News
20 November 2020
PrEP programmes & uptake

Injectable PrEP tops list as the preferred choice for adolescent girls in Cape Town

Editor's pick
Be In The Know
20 November 2020
Government, leadership & policy

NYC’s Leather Daddy HIV Czar Is Going to the CDC—And Advocates Nationwide Are Thrilled

Editor's pick
TheBody
20 November 2020
Tuberculosis & HIV

TB policies aren't working. Here's why.

Editor's pick
Devex
20 November 2020
New & experimental HIV treatments

Data sets up 2021 filings for Gilead's twice-a-year HIV drug lenacapavir

Editor's pick
Pharmaphorum
20 November 2020
Sexually transmitted infections prevention

DoxyPEP for STIs: Are We Ready for Prophylactic Doxycycline for MSM on HIV PrEP?

Editor's pick
TheBodyPro
20 November 2020
Injectable & long-acting HIV treatment

A Long-Lasting, More Effective HIV Drug Is A Psychological Relief For Patients

Editor's pick
NPR
20 November 2020
New & experimental HIV treatments

Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV

Editor's pick
Gilead press release
20 November 2020
HIV treatment for children & young people

WHO and other stakeholders join forces to accelerate access to effective paediatric HIV and tuberculosis diagnostics and medicines

Editor's pick
World Health Organization
20 November 2020
Harm reduction

Harm Reduction “Satellite Sites” Are a Powerful, Underutilized Model

Editor's pick
Filter
20 November 2020
Treatment outcomes & life expectancy

H.I.V. Death Rates Fell by Half 2010-2018, C.D.C. Says

Editor's pick
New York Times
20 November 2020
Sexually transmitted infections prevention

Almost one in ten HIV PrEP users report buying antibiotics for STI prevention, raising concerns over potential antibiotic resistance

News
20 November 2020
Coronavirus

aidsmapCHAT: series 3, episode 2 Video

November 2020
Ageing & HIV

How should we care for older people with HIV?

News
19 November 2020
PrEP programmes & uptake

'Uptake Is Only the First Step' for Effective HIV PrEP Protection

Editor's pick
Medscape (requires free registration)
18 November 2020
Hepatitis C transmission & prevention

WHO-commissioned global systematic review finds high HCV prevalence and incidence among men who have sex with men

Editor's pick
World Health Organization
18 November 2020
Epidemiology

HIV death rate in South African men much higher than in women

Editor's pick
Spotlight
18 November 2020